Nutriband Inc. (NTRB) - Q3 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended October 31, 2024. Nutriband Inc. is a Nevada corporation focused on developing transdermal pharmaceutical products, specifically its lead product, Aversa (an abuse-deterrent fentanyl transdermal system), and providing contract manufacturing services through its subsidiary, Pocono Pharmaceuticals. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended Oct 31, 2024 | Nine Months Ended Oct 31, 2024 |
|---|---|---|
| Revenue | $645,796 | $1,497,158 |
| Net Loss | $(1,362,637) | $(4,966,179) |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.48) |
| Cash and Cash Equivalents | $5,698,187 | $5,698,187 (Ending Balance) |
| Working Capital | $4,943,816 | $4,943,816 (Ending Balance) |
| Operating Cash Flow | N/A | $(3,387,320) Used |
| Financing Cash Flow | N/A | $8,684,608 Provided |
| Total Debt (Current + Long-Term) | $191,617 | $191,617 |
Note: Gross margin for the nine months ended Oct 31, 2024, was approximately 30.6% ($457,373 gross profit on $1,497,158 revenue).
Material Changes vs. Prior Period
- Liquidity Surge: Cash and cash equivalents increased from $492,942 (Jan 31, 2024) to $5,698,187 (Oct 31, 2024), driven primarily by an $8.4 million equity financing in April 2024.
- Revenue Composition: Revenue for the nine months ended Oct 31, 2024, was entirely derived from the "Sale of Goods" segment (Pocono Pharmaceuticals). The "Services" segment (4P Therapeutics contract R&D) generated $0 revenue in the current period, compared to $165,034 in the prior year period.
- Expense Trends: Research and Development (R&D) expenses increased significantly to $2,629,278 for the nine months ended Oct 31, 2024, compared to $1,397,055 in the prior year, due to increased development costs for the Aversa product with Kindeva Drug Delivery. Selling, General, and Administrative (SG&A) expenses decreased to $2,554,155 from $2,849,399 in the prior year.
- Debt Extinguishment: The company recorded a $368,036 loss on the extinguishment of debt in the current nine-month period, resulting from converting $300,000 of related-party debt into equity and warrants.
Outlook, Risks, and Management Commentary
- Going Concern: Management believes substantial doubt regarding the company's ability to continue as a going concern has been alleviated due to the recent $8.4 million equity financing and a $5 million credit line facility. They project sufficient funds to operate for the next 12 months.
- Product Development: The company is in the clinical supply phase for its lead product, Aversa Fentanyl. An agreement with Kindeva Drug Delivery is estimated to cost $8.1 million total; approximately $1.8 million has been incurred, with $6.3 million expected in future costs. FDA submission is expected in 12-18 months.
- Legal Proceedings: The company is a defendant in a lawsuit by Joseph Gunnar, LLC, and Lucosky Brookman LLP alleging breach of contract and fraud regarding a terminated engagement letter. Plaintiffs seek over $500,000 plus punitive damages. The company has filed counterclaims seeking $2 million. No hearings are currently pending.
- Internal Controls: Management concluded that disclosure controls and procedures are not effective due to material weaknesses, including a lack of segregation of duties and reliance on third-party consultants, though they have recently added qualified accounting personnel.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $5.7 million cash balance against the projected $6.3 million remaining cost for the Aversa FDA submission and ongoing operating losses.
- Revenue Visibility: Confirm the status of the "Services" segment (4P Therapeutics), which generated zero revenue in the current period, and assess reliance on the "Sale of Goods" segment (Pocono Pharmaceuticals).
- Legal Exposure: Monitor the status of the Gunnar/LB lawsuit and the potential impact of the $2 million counterclaim or the plaintiffs' $500,000+ claim.
- Equity Dilution: Review the impact of the recent $8.4 million financing and the conversion of debt on shareholder dilution, noting the issuance of 2.1 million shares and 4.2 million warrants in the April offering.
- Internal Control Remediation: Assess the timeline and effectiveness of the company's plan to remediate material weaknesses in internal controls over financial reporting.